参考文献/References:
[1] Ostrom QT, Gittleman H, Stetson et al. Epidemiology ofgliomas [J]. Cancer Treat Res, 2015, 163: 1-14.
[2] Ostrom QT, Bauchet L, Davis FG, et al. The epidemiology of glioma in adults: a "state of the science" review [J]. Neuro Oncol, 2015, 17(4): 623-624.
[3] Bair SM, Porter DL. Accelerating chimeric antigen receptor therapy in chronic lymphocytic leukemia: the development and challenges of chimeric antigen receptor T-cell therapy for chronic lymphocytic leukemia [J]. Am J Hematol, 2019,94(S1): 10-17.
[4] Kloss CC, Lee J, Zhang A, et al. Dominant-negative TGF-beta receptor enhances PSMA-targeted human CAR T cell proliferation and augments prostate cancer eradication [J]. Mol Ther, 2018, 26(7): 1855-1866.
[5] Bouchkouj N, Kasamon YL, de Claro RA, et al. FDAapproval summary: axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma [J]. Clin Cancer Res, 2019, 25(6): 1702-1708.
[6] 郑 晓，蒋敬庭. CAR-T细胞治疗的现状与临床应用前景[J]. 临床肿瘤学杂志，2018，23（7）：655-660.
[7] Diehn M, Alizadeh AA, Rando OJ, et al. Genomic expres-sion programs and the integration of the CD28 costimula-tory signal in T cell activation [J]. Proc Natl Acad Sci USA, 2002, 99(18): 11796-11801.
[8] Rosenberg SA. IL-2: the first effective immunotherapy for human cancer [J]. J Immunol, 2014, 192(12): 5451-5458.
[9] 葛玉凤，韩东晖，吴介恒，等. CAR-T细胞治疗用于实体瘤的研究进展[J]. 转化医学电子杂志，2017，4（10）：50-55.
[10] Eyquem J, Mansilla-Soto J, Giavridis T, et al. Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection [J]. Nature, 2017, 543(7643): 113-117.
[11] Shum T, Omer B, Tashiro H, et al. Constitutive signaling from an engineered IL7 receptor promotes durable tumor elimination by tumor-redirected T cells [J]. Cancer Discov, 2017, 7(11): 1238-1247.
[12] Ren J, Liu X, Fang C, et al. Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition[J]. Clin Cancer Res, 2017, 23(9): 2255-2266.
[13] Cherkassky L, Morello A, Villena-Vargas J, et al. Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition [J]. J Clin Invest, 2016,126(8): 3130-3144.
[14] Hegde M, Mukherjee M, Grada Z, et al. Tandem CAR T cells targeting HER2 and IL13Ralpha2 mitigate tumor antigen escape [J]. J Clin Invest, 2016, 126(8): 3036-3052.
[15] Bielamowicz K, Fousek K, Byrd TT, et al. Trivalent CAR T cells overcome interpatient antigenic variability in glioblas-toma [J]. Neuro Oncol, 2018, 20(4): 506-518.
[16] 白 玥，钟晓松，李文斌. 嵌合抗原受体T细胞治疗多形性胶质母细胞瘤的最新进展[J]. 中国肿瘤临床，2017，44（16）：794-799.
[17] Brudno JN, Kochenderfer JN. Toxicities of chimeric antigen receptor T cells: recognition and management [J]. Blood, 2016, 127(26): 3321-3330.
[18] Brown CE, Badie B, Barish ME, et al. Bioactivity and safety of IL13Ralpha2-redirected chimeric antigen receptor CD8+T cells in patients with recurrent glioblastoma [J]. Clin Cancer Res, 2015, 21(18): 4062-4072.
相似文献/References:
[1]谢宝树 张 林 王 宇 贾 锋 殷玉华.复发性多发胶质母细胞瘤的预后分析[J].中国临床神经外科杂志,2016,(06):333.[doi:10.13798/j.issn.1009-153X.2016.06.005]
XIE Bao-shu,ZHANG Lin,WANG Yu,et al.Analysis of prognoses in patients with recurrent multiple glioblastomas[J].,2016,(06):333.[doi:10.13798/j.issn.1009-153X.2016.06.005]
[2]宋贵东 综述 高之宪 审校.贝伐单抗治疗复发胶质母细胞瘤的研究进展[J].中国临床神经外科杂志,2015,(10):638.[doi:10.13798/j.issn.1009-153X.2015.10.022]
[3]李继强 杨吉安 邵灵敏 吴庭枫 刘宝辉 陈谦学.稳定低表达BAG3的胶质母细胞瘤U87细胞株的构建及鉴定[J].中国临床神经外科杂志,2015,(06):353.[doi:10.13798/j.issn.1009-153X.2015.06.011]
LI Ji-qiang,YANG Ji-an,SHAO Ling-min,et al.Construction and identification of U87 glioblastoma cell strain with a stable low expression of BAG3[J].,2015,(06):353.[doi:10.13798/j.issn.1009-153X.2015.06.011]
[4]桂志勇 冯 军 黄俊红 白敬洋.靶向沉默c-fos基因表达对胶质瘤U87MG细胞增殖与侵袭的影响[J].中国临床神经外科杂志,2017,(12):834.[doi:10.13798/j.issn.1009-153X.2017.12.011]
GUI Zhi-yong,FENG Jun,HUANG Jun-hong,et al.Effects of c-fos targeted silence on proliferation and invasiveness of human glioma cell U87[J].,2017,(06):834.[doi:10.13798/j.issn.1009-153X.2017.12.011]
[5]王娇燕 孟凡华 刘魏然 魏春晓 林丽萍.SWI在胶质母细胞瘤与单发脑转移瘤鉴别中的价值[J].中国临床神经外科杂志,2018,(01):13.[doi:10.13798/j.issn.1009-153X.2018.01.005]
WANG Jiao-yan,MENG Fan-hua,LIU Wei-ran,et al.Value of susceptibility-weighted imaging in differentiative diagnosis of glioblastomas and solitary brain metastases[J].,2018,(06):13.[doi:10.13798/j.issn.1009-153X.2018.01.005]
[6]张治元 王汉东 樊友武 贾 玥 吴晋蓉.胶质肉瘤15例分析及文献复习[J].中国临床神经外科杂志,2018,(02):69.
ZHANG Zhi-yuan,WANG Han-dong,FAN You-wu,et al.Diagnosis and treatment of gliosarcoma: a report of 15 cases and literature review[J].,2018,(06):69.
[7]郑锐哲 姜秀峰 陈二涛 孙兆良 冯东福.胶质母细胞瘤卒中术后继发硬膜下水瘤1例[J].中国临床神经外科杂志,2019,(02):128.[doi:10.13798/j.issn.1009-153X.2019.02.022]
[8]胡 玥,薛小燕,李子超,等.阿苯达唑抑制胶质瘤裸鼠模型肿瘤生长[J].中国临床神经外科杂志,2019,(06):348.[doi:10.13798/j.issn.1009-153X.2019.06.010]
HU Yue,XUE Xiao-yan,LI Zi-chao,et al.Albendazole inhibits tumor growth in nude mice model of glioma[J].,2019,(06):348.[doi:10.13798/j.issn.1009-153X.2019.06.010]
[9]殷安安 陆 南 贺亚龙 章 翔 刘玉河.TRIM38基因非CpG岛DNA甲基化与胶质母细胞瘤临床预后的关系[J].中国临床神经外科杂志,2020,(02):76.[doi:10.13798/j.issn.1009-153X.2020.02.005]
YIN An-an,LU Nan,HE Ya-long,et al.Impacts of TRIM38 non-CpG island DNA methylation alterations on clinical prognosis in patients with glioblastomas[J].,2020,(06):76.[doi:10.13798/j.issn.1009-153X.2020.02.005]
[10]吴 蛟 易 勇 赵卓琳 周良学 周世军.贝伐珠单抗联合化疗治疗胶质母细胞瘤的meta分析[J].中国临床神经外科杂志,2020,(02):82.[doi:10.13798/j.issn.1009-153X.2020.02.007]
WU Jiao,YI Yong,ZHAO Zhuo-lin,et al.Efficacy and safety of bevacizumab combined with chemotherapy for glioblastoma: a meta-analysis[J].,2020,(06):82.[doi:10.13798/j.issn.1009-153X.2020.02.007]